Actavis operates 14 manufacturing sites in 12 different countries: US, Bulgaria, Iceland, China, Italy, India, Indonesia, Malta, Romania, Russia, Serbia, and the UK.

United States (2)
Oral solids, liquids, creams, ointments
Actavis has manufacturing sites for solid, liquid, and semi-solid dosage forms in the United States: in Elisabeth, NJ and Lincolnton, NC.

• Elizabeth, NJ: Solid-oral-dose facility for tablets and capsules supporting a broad therapeutic range. Core competency in modified-release products.
• Lincolnton, NC: A growing production site for creams, ointments, liquids, and suppository products serving the OTC, branded, and Rx markets in the US. Leading supplier of first aid, feminine hygiene, hydrocortisone, anti-fungal, and permethrin products for private label and own-label sales.

Iceland (1)
Oral solids and related products
Actavis has one production plant operating to EU standards manufacturing tablets and capsules for Western European markets. Iceland is the principal launch site for new Actavis products.

UK (1)
Oral solids & suppository
An EU GMP approved large solid-oral-dosage facility, the Barnstaple plant has a capacity of 5.5 billion tablets and capsules serving the generic, OTC and Rx markets in Europe, the Middle East, and Africa. This site has successfully maintained a highly competitive low-cost position (comparable to Indian suppliers). Increased capacity in this facility is planned for the coming years.

Bulgaria (2)
Oral solids, infusion solutions, creams, ointments
Actavis has two sites in Bulgaria: Dupnitza and Troyan. The Bulgarian sites are operating according to Bulgarian and EU GMP standards. These sites produce a wide range of formulations, including tablets, creams, ointments, and capsules.

Italy (1)
Cytostatics and anaesthetics
Actavis acquired a facility in Nerviano, Italy in 2008. The facility produces sterile products using aseptic processing and terminal sterilisation. Its main product types are cytostatics and anaesthetics.

Malta (1)
Oral solids
A refurbished facility with skilled employees, EU GMP approval, and high-volume capacity make the Malta plant a vital supply source for Actavis’ Western European markets. A very significant capacity expansion, both in bulk and packaging, was completed in 2007. 

Serbia (1)
Mostly oral solids
Zdravlje, an Actavis Company, specialises in gastroenterology and cardiology products. The business has been streamlined to reflect the Group’s core business. This facility has recently completed a significant upgrade and is capable of supplying Western European markets in 2009. The plant received ISO 14001 (EHS) certification in 2006, ISO 9001 : 2001 (Quality) and OHSAS 18001 (EHS) Certificates in 2007 and is EU GMP certified by DKMA (Danish Medicinal Agency) in 2008 and 2009.

Romania (1)
Oncology
Actavis in Romania manufactures and distributes a wide range of oncology compounds. The facility is approved by the MHRA for sales in the European Union and was successfully inspected by the FDA in January 2007.

Russia (1)
Tablets and capsules
Actavis owns a 51% stake in the Russian pharmaceuticals manufacturer ZiO Zdorovje, which is located in Podolsk (about 20 kilometres from Moscow) . The factory has local GMP approval and ISO 9001:2000 certification. This facility is currently undergoing an expansion programme that will be completed in 2008.

China (1)
Oral solids, powders, syrup, semi solids
The Foshan plant produces a range of generic pharmaceuticals and traditional Chinese medicines in tablet, capsule, liquid, cream and powder forms. Serving the local Chinese market, the site has obtained local GMP approval.

Indonesia (1)
Oral Solid Dosage Forms (Penicillin as well as Non-Penicillin), Liquids, Creams and Ointments
The Jakarta facility produces dry powder for oral use, topical products, tablets and capsules. The plant is EU GMP approved. The facility currently serves Singapore, Hong Kong, Sri Lanka, Australia, and a number of EU and EEA countries, in addition to the domestic market.

India (1)
Oral solids and contract manufacturing
Actavis operates one manufacturing facilitiy in India, based in Chennai.

• Actavis Alathur Pharma is a manufacturing facility for oral-solid-dosage products with a future capacity of four billion units. The site has FDA approval.